Onset: 30-60 min for any first-day perception, but the prominent benefit emerges over days 5-14 as antioxidant enzyme upregulation accumulates. Peak plasma at 30-60 min, 4-5 hour half-life means TID dosing keeps coverage steady.

Characteristic phenomenology (compiled from Russian clinical descriptors + biohacker reports):

• "Calm clarity" — anxiety reduction without sedation, emotional blunting, or cognitive fog
• Improved sleep onset latency for users with anxious-presleep rumination
• Subtle reduction in subjective oxidative-stress symptoms (post-stimulant fatigue, post-illness brain fog)
• No acute "kick" or perceptible stimulation; very subtle profile compared to bromantane or modafinil
• Reports of clearer thinking around week 2 — likely the antioxidant arm catching up
• Notable subset (~25-35%) feels little or nothing — this is a real failure mode

Compared to Selank: Selank is a peptide (intranasal) with faster anxiolytic onset, similar non-sedating profile, and better-characterized clinical data. Mexidol adds the antioxidant + bioenergetic arms but loses the acute anxiolytic kick.

Compared to ashwagandha (KSM-66 / Sensoril): Ashwagandha is the cleaner Western-evidence anxiolytic with broader stacking compatibility. Mexidol's distinctive value over ashwagandha is the mitochondrial bioenergetic support, not the anxiolytic effect itself.

Compared to NAC: Both antioxidants, but operate through different pathways — NAC restores glutathione substrate (cysteine donor), mexidol scavenges radicals directly and upregulates the glutathione-using enzymes. They stack additively rather than redundantly.

• Tolerance buildup: minimal-to-none in available data. Russian clinical use across multi-week courses shows no escalation requirement. Mechanism is consistent: antioxidant enzyme upregulation does not produce receptor downregulation, and GABA-A indirect modulation does not generate the kind of receptor-internalization-driven tolerance seen with benzodiazepines.
• Recommended cycle: 4-6 weeks on / 2-3 weeks off for biohacker use. Russian clinical practice can extend to 8-12 weeks, but in the absence of medical monitoring the conservative cycle is safer.
• Reset protocol if needed: 2-3 weeks complete washout. Subjective benefit returns at baseline on next cycle. No reports of "kindling" or accelerated tolerance with repeated cycles.

Synergistic with

• N-Acetyl-Cysteine (NAC): Complementary antioxidant pathways — NAC restores glutathione substrate, mexidol scavenges radicals directly + upregulates the glutathione-using enzymes. Standard pairing in Russian neuro-recovery protocols. Both are in the canonical stack-compatible category.
• Selank: Both Russian-developed anxiolytics, non-overlapping mechanisms. Selank acts on enkephalinase/GABA via its tuftsin-analog peptide structure (intranasal); mexidol provides antioxidant + indirect GABA-A potentiation (oral). Layered anxiolysis without sedation.
• Semax / N-Acetyl-Semax-Amidate: Different layer — Semax raises BDNF/NGF (neurotrophic), mexidol provides antioxidant/membrane stabilization. Common Russian-stack neurorehab combination.
• Bromantane: Bromantane upregulates DA synthesis enzymes; mexidol mitigates any oxidative load from upregulated DA turnover. Theoretical synergy not yet formally tested in humans.
• L-theanine: Both mild GABA-modulators with non-sedating profiles. Smoothing partner for mexidol's anxiolytic arm.
• Modafinil: Anecdotally used to soften modafinil's anxiogenic edge. No documented interaction; mechanisms are non-overlapping.

Avoid stacking with

• Benzodiazepines (alprazolam, diazepam): Additive GABA-A potentiation. Russian clinical practice uses this to reduce benzo doses, but uncontrolled biohacker use is risky. Skip without clinical oversight.
• Phenibut / GABA-B agonists: Theoretical additive sedation through different GABA receptor subtypes. Not a safety crisis but compounds the ataxia risk if dosed late or aggressively.
• High-dose alcohol: Mexidol is used in alcohol withdrawal protocols, but acute co-ingestion with active drinking is not characterized — theoretical additive CNS depression. Russian practice is post-withdrawal use, not concurrent.

Neutral / safe co-administration

The full canonical V4 stack — DHA, magnesium glycinate, citicoline, NAC, phosphatidylserine, curcumin, rhodiola, theanine, D3+K2, beta-alanine, vitamin C — is fully compatible with mexidol. No documented or theoretical conflicts.

• CYP enzymes: Limited Western pharmacology data. Russian sources do not report significant CYP induction or inhibition. Theoretical mild CYP3A4 effect via the pyridine ring but unconfirmed.
• Antidepressants (SSRIs, SNRIs): No documented direct interaction. Theoretical caution with benzodiazepine-co-prescribed SSRI patients due to GABA arm.
• Anticoagulants: No data; the antioxidant arm may theoretically affect platelet function but no clinical reports.
• Anticonvulsants: Mexidol has anticonvulsant activity in animal models; Russian neurology uses it as adjunct to standard anticonvulsants. May potentiate.
• MAOIs: No theoretical or documented interaction — mexidol does not affect monoamine metabolism.
• Hormonal contraceptives: No data; assume no interaction in the absence of significant CYP effect.

No published pharmacogenomic data for mexidol specifically. Theoretical considerations:

• Antioxidant enzyme polymorphisms (SOD2 Ala16Val, GPX1 Pro198Leu): Carriers of low-activity variants might gain more from mexidol's enzyme-upregulation arm.
• GABA-A subunit polymorphisms: Could affect responsiveness to the indirect potentiation arm.
• CYP2D6 / CYP3A4: Plausible relevance if mexidol is metabolized through these pathways, but no clinical reports.
• The user's 23andMe results (June 2026) won't directly inform mexidol dosing but could inform broader antioxidant-system status if SOD/GPx variants are reported.

Sourcing reality 2026: Authentic Russian pharmacy-grade Mexidol (Farmasoft brand, originator) is the gold standard but requires gray-market import from Russia, with 2-4 week shipping and customs uncertainty. Western research-chem capsules (RUO, Kimera Chems) are convenient and provide COA verification but are formally "research use only." Research-chem powder is cheapest per gram but requires precise weighing (125 mg dose accuracy on a 0.001 g scale is non-trivial). Recommendation for users in this archetype: RUO or Kimera Chems 125 mg capsules with COA — minimizes dose-error risk and avoids customs complexity.

Cost target: ~$30-50/month at 125 mg BID-TID dosing.

• Baseline (before starting): Anxiety scale (GAD-7 or HAM-A), subjective sleep onset latency, subjective post-stimulant recovery quality. Optional but useful: oxidative stress markers (8-OHdG urine, F2-isoprostanes, MDA), SOD/GPx activity if available, hs-CRP.
• During use (week 1, week 4): Same anxiety + sleep scales; subjective clarity score (1-10 daily). Watch for paradoxical irritability or excess drowsiness.
• Cycling beyond 6 weeks: CBC, LFTs (ALT/AST), comprehensive metabolic panel.
• Post-cycle: Repeat baseline scales 1, 2 weeks post-discontinuation. Effects taper smoothly within 1-2 weeks; no rebound phenomenon documented.